Zonisamide improves parkinsonism in DLB patients: A randomized phase 3 trial
Objective: To verify the efficacy and safety of zonisamide (ZNS) for parkinsonism in patients with dementia with Lewy bodies (DLB). Background: DLB parkinsonism is responsive…Expanding the NINDS Parkinson’s Disease Biomarkers Program – Utilizing a Major Biomarker Resource to Address Atypical Parkinsonisms and Related Conditions
Objective: Expansion of a carefully curated resource for clinical and biosample data to address a critical need for biomarker discovery in Atypical Parkinsonisms and related…Efficacy of zonisamide on motor symptoms in dementia with Lewy bodies: A post-hoc analysis of a phase 3 study
Objective: To characterize the efficacy of zonisamide in improving motor symptoms, we performed a post-hoc analysis using data from a phase 3 study that evaluated…Neuropsychological and clinical assessment for the differential diagnosis of patients with PDD vs. DLB
Objective: To explore the role of clinical neuropsychological tools in Parkinson’s disease-dementia (PDD) vs. dementia with Lewy bodies (DLB). First, to define the feasibility of…Motor and non-motor correlates of APOE-ε4 mediated cerebrospinal fluid concentrations of amino acids and monoamine metabolites in dementia with Lewy bodies compared with Alzheimer’s dementia and healthy controls
Objective: To study associations of cerebrospinal fluid (CSF) amino acids and monoamine metabolites with motor and non-motor features in dementia with Lewy bodies (DLB) compared…Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies
Objective: Efficacy and safety of rivastigmine solution in the treatment of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) is not well studied…Angiotensin-converting enzyme inhibitors are neuroprotective regarding APOE-mediated motor and non-motor experiences for Alzheimer’s dementia but not for dementia with Lewy bodies
Objective: To assess whether angiotensin-converting enzyme (ACE) inhibitors modulate associations of biofluid concentrations and activity of ACE with motor and non-motor experiences in dementia with…Dual task walking differentially affects toe clearance in Lewy body disease: A contributor to dynamic falls risk?
Objective: To evaluate the change in gait and minimum toe clearance when walking under dual task in different dementia sub-types as a contributor to dynamic…Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies
Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?
Objective: The objective of this work is to study the interaction between α-synuclein and the insulin degrading enzyme in the pancreas of subjects with synucleinopathies.…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 25
- Next Page »